Although DSM-5 diagnosis is defined through multiple behavioral criteria encompassing impaired control, social dysfunction, continued use despite harm, and tolerance or withdrawal, converging clinical and preclinical evidence indicates that the core pathological feature of SUDs is the progressive loss of control over intake (O'Brien, 2005)
This inhibition can lead to a reduction in dark spots and an overall lightening of the skin tone
However, compared with appetite-suppressing drugs, Vutiglabridin produces a slower onset and a smaller magnitude of weight loss [24, 25]
Although laboratory alterations are seen, such as a reduction in serum T 4 by 25%, T 3 by 15% and a 2 mU/L rise in TSH, these values remain within the normal ranges without clinical signs of thyroid dysfunction ( A failure of the Wolff-Chaikoff effect can give rise to the Jod-Basedow phenomenon, typically seen in patients with impaired thyroid regulation, including those with thyroid nodules
Scope for guideline update (starting 2025) MASLD (GID-NG10434)